Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) ...
UniQure stock dropped after the FDA sent feedback on the company's pending treatment for Huntington's disease. Read more on ...
15hon MSN
First-in-human trial of CRISPR gene-editing therapy safely lowers cholesterol and triglycerides
In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...
On a more microscale (literally), microlearning has been shown to help “protect mental health and support resilience” by ...
The U.S. health care reimbursement system was built for a different era — one that prioritized high-stakes “cure” interventions over “care” interventions we need now.
The companies will use clinical trial plasma samples and data to drive the AthosOmics.AI platform to identify efficacy biomarkers for Xeptiva's lead experimental therapeutic vaccine for canine ...
A Gene-Editing Therapy Cut Cholesterol Levels by Half An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise ... of our lives—from culture to business, science to ...
Access to funding, technology fragmentation, and a misalignment with farmers’ needs are perennial barriers to the adoption of ...
UBS Global Healthcare Conference 2025 November 10, 2025 8:00 AM ESTCompany ParticipantsMaxwell Krakowiak - Senior VP ...
News-Medical.Net on MSN
One-time CRISPR therapy safely lowers cholesterol and triglycerides in early trial
In a 15-patient, Phase 1 one, first-in-human trial, a one-time, CRISPR-Cas9 gene-editing therapy safely reduced LDL ...
CRISPR-Cas9 is a promising approach for obesity therapy, targeting key genes involved in appetite regulation, metabolism, and fat storage. Preclinical studies showed strong metabolic benefits, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback